Drug Target Review

NOVEMBER 7, 2023

Chemists at Stanford University discovered how one of the pathways leading to this protein “woodchipper” works furthering the understanding of new therapeutics for autoimmune diseases, age-related disorders, and treatment-resistant cancers. Enzyme replacement therapy is a frequent treatment for these disorders.

Therapies 59

Therapies Science Disease Treatment 59

The Pharma Data

DECEMBER 8, 2020

Blood disease trial participants given Vertex’s and CRISPR Therapeutics’ CRISPR/Cas9-based gene-editing therapy CTX001 demonstrated a “consistent and sustained response” to the treatment, according to new phase 1/2 trial data the companies have announced. To date, a total of 19 trial participants have been dosed with the gene therapy.

Therapies 52

Therapies Clinical Trials Trials Treatment 52

The Pharma Data

APRIL 7, 2022

This unprecedented CMS decision effectively denies all Medicare beneficiaries access to ADUHELM ® (aducanumab-avwa), the first and only FDA-approved therapy in a new class of Alzheimer’s drugs. It may also limit coverage for any future approved treatment in the class. ADUHELM is indicated for the treatment of Alzheimer’s disease.

Treatment 52

Treatment Therapies Disease FDA Approval 52

Broad Institute

NOVEMBER 6, 2024

For some patients, this treatment results in striking and long-lasting remission — but for a subset, it triggers complications ranging from mild rash to potentially deadly brain and heart inflammation. These are home-run, breakthrough therapies, and quite an amazing success story.

Research 124

Research Immune Response Hospitals Therapies 124

The Pharma Data

MAY 27, 2022

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response . In December 2017, Janssen Biotech, Inc. to develop and commercialise cilta-cel.[1].

Therapies 52

Therapies Treatment Pharmaceutical Companies Nurses 52

The Pharma Data

NOVEMBER 18, 2020

Over the past decade, the world has witnessed unprecedented scale-up of antiretroviral therapy (ART), which has saved the lives of tens of millions of people. Standardized surveillance of HIV drug resistance provides countries with actionable evidence that is used to optimize patient and population-level treatment outcomes. infants.

Laboratories 52

Laboratories Therapies Virus Government 52

The Pharma Data

NOVEMBER 3, 2020

4, 2020 /PRNewswire/ — Q3 2020 highlights. m (-), including US launch of the scientifically proven digital therapies deprexis® and vorvida®. Updated financial outlook 2020. 2020 Jul-Sep. 2020 Jan-Sep. m (90.9).

Therapies 52

Therapies Production Pharmaceuticals Marketing 52

The Pharma Data

NOVEMBER 18, 2020

-based Obsidian Therapeutics and the University of Texas’ MD Anderson Cancer Center have forged a multi-year deal to develop tumor-infiltrating lymphocytes (TILs) as a treatment for solid tumors. Source link.

Therapies 52

Therapies Treatment Disease Research 52

The Pharma Data

NOVEMBER 30, 2020

The UK-based RECOVERY trial, which is evaluating multiple treatments for COVID-19, will add the inexpensive anti-inflammatory drug colchicine to the list of therapies being tested in hospitalized patients.

Treatment 52

Treatment Trials Hospitals Therapies 52

The Pharma Data

NOVEMBER 25, 2020

AHA: Ablation Better Than Meds for Initial A-Fib Treatment. 25, 2020 — Cryoballoon ablation is superior to drug therapy as an initial treatment for the prevention of atrial arrhythmia recurrence in patients with paroxysmal atrial fibrillation , according to a study published online Nov. © 2020 HealthDay.

Treatment 52

Treatment Therapies Disease Drugs 52

Drug Target Review

SEPTEMBER 25, 2024

Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades. The reactivation of oncogenic signalling upstream or downstream of the driving oncogene is a well-studied source of resistance to targeted cancer therapies.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

NOVEMBER 8, 2020

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. LONDON and RALEIGH, N.C.,

Therapies 52

Therapies Treatment Disease Hospitals 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Therapies 52

Therapies Clinical Trials FDA Production 52

Eye on FDA

MARCH 5, 2023

Note these numbers cover meetings about drug applications only, not including vaccines or cellular therapies. That said, beginning in 2020 meetings began skewing to more negative outcomes and 2022 was the first year where the number of negative outcomes outweighed the number of positive outcomes.

FDA 72

FDA Vaccine Drugs Therapies 72

Drug Target Review

JULY 1, 2024

As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. Could you elaborate on the potential market size for SRP-001 and how it fits into the broader landscape of pain therapies? South Rampart Pharma, Inc.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

The Pharma Data

MARCH 9, 2022

Investigators at Cedars-Sinai have identified a potential new therapy for COVID-19: a biologic substance created by reengineered human skin cells. Although still in the early stages, the findings open the possibility of having a new therapy for COVID-19 patients.

Treatment 52

Treatment Virus Engineering Therapies 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of next generation drugs for the treatment of cancer. BUFFALO, N.Y., Founded in 2003, Athenex, Inc.

Engineering 52

Engineering Therapies Treatment International 52

The Pharma Data

DECEMBER 29, 2020

Primary Aldosteronism Testing Rare in Treatment-Resistant HTN. 29, 2020 — Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism, according to a study published online Dec. Veterans Health Administration with apparent treatment-resistant hypertension from 2000 to 2017.

Treatment 52

Treatment International Therapies Research 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. Nestlé Health Science has a history of advancing nutritional therapies.

Science 52

Science Disease Pharmaceuticals Treatment 52

The Pharma Data

DECEMBER 21, 2020

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer. 21, 2020 — Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. © 2020 HealthDay. Posted: December 2020. MONDAY, Dec. More Information.

FDA Approval 52

FDA Approval Therapies FDA Science 52

The Pharma Data

OCTOBER 22, 2020

CRISPR Therapeutics has reported positive results for a phase 1 study evaluating CTX110, its chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory nonHodgkin’s lymphoma in patients who have received at least two prior lines of therapy. Source link.

Treatment 40

Treatment Therapies Trials Pharmaceuticals 40

The Pharma Data

JANUARY 3, 2021

(Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that U.S. GM1 is a rare and often life-threatening CNS disorder with no approved disease-modifying therapies available. chief medical officer of Passage Bio. About PBGM01.

Therapies 52

Therapies FDA Treatment Clinical Trials 52

The Pharma Data

SEPTEMBER 21, 2020

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) were revealed at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Therapies 52

Therapies Treatment Disease 52

The Pharma Data

NOVEMBER 23, 2020

FDA Authorizes Use of Monoclonal Antibody Treatment for COVID-19. 23, 2020 — A combination of two monoclonal antibodies was granted emergency use authorization (EUA) for the treatment of mild-to-moderate COVID-19, the U.S. © 2020 HealthDay. Posted: November 2020. Professional. MONDAY, Nov. More Information.

FDA 52

FDA Treatment Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

20, 2020 — Hormone therapy can be a lifesaver for men with prostate cancer , but it also appears to put some at increased risk of heart problems, a new study reports. “We need to do everything we can to ensure the patients can receive lifesaving cancer therapy in a safe manner,” Ky said. FRIDAY, Nov.

Therapies 52

Therapies Doctors Disease Treatment 52

The Pharma Data

JANUARY 12, 2021

Preliminary revenue for the fourth quarter of 2020 is expected to be approximately $40.6 Preliminary revenue for the fourth quarter of 2020 is expected to be approximately $40.6 Preliminary revenue for the full year 2020 is expected to be approximately $125.4 2020 was a transformational year for Vapotherm.

Therapies 52

Therapies Production Marketing Regulations 52

The Pharma Data

SEPTEMBER 1, 2020

Daiichi Sankyo has unveiled promising new benefit for Nilemdo (bempedoic acid) at the ESC Congress 2020 over the weekend for the management of low-density lipoprotein cholesterol (LDL-C) when added to other standards of care. compared to placebo on top of maximally tolerated statin therapy and other LLTs throughout the 78 weeks.

Clinical Trials 52

Clinical Trials Trials Treatment Therapies 52

The Pharma Data

OCTOBER 19, 2020

Anti-VEGF Therapy May Aid Visual Acuity in Some nAMD Patients. 19, 2020 — For about 20 percent of patients with neovascular age-related macular degeneration (nAMD), useful visual acuity (VA) is preserved with anti-vascular endothelial growth factor (VEGF) treatment, according to a study published online Oct. Professional.

Therapies 52

Therapies Treatment Pharmaceuticals Disease 52

The Pharma Data

SEPTEMBER 10, 2020

The EMA has asked for full data from an ongoing Phase III study of the treatment in patients with severe haemophilia A. European regulators have requested more data to review the marketing application for BioMarin’s haemophilia A gene therapy Valrox (valoctocogene roxaparvove).

Therapies 52

Therapies Regulations Treatment Marketing 52

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. In addition, health-related quality of life (HRQoL), per total Functional Assessment of Cancer Therapy–Prostate (FACT-P), continued to be maintained with ERLEADA ®.

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

The Pharma Data

DECEMBER 27, 2020

28, 2020 /PRNewswire/ — C-RAD announces today that C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the US. C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy – Catalyst PT.

Treatment 52

Treatment Therapies Regulations Marketing 52

The Pharma Data

DECEMBER 22, 2020

Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations. 22, 2020 — Tagrisso ( osimertinib ) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. © 2020 HealthDay.

Therapies 52

Therapies Treatment FDA Disease 52

The Pharma Data

DECEMBER 9, 2020

9, 2020 — Side effects of radiation therapy in breast cancer patients are often missed by doctors, U.S. It was common for treatment side effects such as pain, itchy skin, swelling and fatigue to go unrecognized. © 2020 HealthDay. Posted: December 2020. WEDNESDAY, Dec. researchers report. All rights reserved.

Therapies 52

Therapies Doctors Research Treatment 52

The Pharma Data

OCTOBER 26, 2020

ASTRO Issues Guideline on Radiation Therapy for Rectal Cancer. 26, 2020 — In a clinical practice guideline issued by the American Society for Radiation Oncology, published online Oct. In select patients, nonoperative management is conditionally recommended if a clinical complete response is achieved after neoadjuvant treatment.

Therapies 52

Therapies Hospitals International Treatment 52

Broad Institute

NOVEMBER 6, 2024

Launched in 2017, this is a first-of-its-kind program in North America focused on improving the diagnosis, treatment, and understanding of serious immunotherapy complications, which can affect nearly every organ system.

Immune Response 118

Immune Response Medical Schools Clinical Trials Treatment 118

The Pharma Data

APRIL 15, 2022

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S. 2 omicron subvariant.

Treatment 52

Treatment Virus Laboratories Engineering 52

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020 3.

Therapies 40

Therapies Disease Treatment FDA Approval 40